NasdaqGS:CSII

Stock Analysis Report

Executive Summary

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Cardiovascular Systems's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CSII has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.4%

CSII

0.9%

US Medical Equipment

-0.2%

US Market


1 Year Return

44.0%

CSII

23.0%

US Medical Equipment

16.1%

US Market

Return vs Industry: CSII exceeded the US Medical Equipment industry which returned 23% over the past year.

Return vs Market: CSII exceeded the US Market which returned 16.1% over the past year.


Shareholder returns

CSIIIndustryMarket
7 Day4.4%0.9%-0.2%
30 Day-5.6%5.4%3.7%
90 Day-8.2%4.7%8.5%
1 Year44.0%44.0%24.1%23.0%18.7%16.1%
3 Year69.1%69.1%88.0%82.4%46.9%37.4%
5 Year45.3%45.3%115.7%92.4%61.8%44.0%

Price Volatility Vs. Market

How volatile is Cardiovascular Systems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cardiovascular Systems undervalued compared to its fair value and its price relative to the market?

10.97x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: CSII ($44.28) is trading above our estimate of fair value ($13.1)

Significantly Below Fair Value: CSII is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CSII is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CSII is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CSII's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CSII is overvalued based on its PB Ratio (11x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Cardiovascular Systems forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

82.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CSII is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: CSII is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CSII's is expected to become profitable in the next 3 years.

Revenue vs Market: CSII's revenue (14.3% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CSII's revenue (14.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CSII's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cardiovascular Systems performed over the past 5 years?

53.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CSII has high quality earnings.

Growing Profit Margin: CSII is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CSII is unprofitable, but has reduced losses over the past 5 years at a rate of 53.5% per year.

Accelerating Growth: Unable to compare CSII's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CSII is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).


Return on Equity

High ROE: CSII has a negative Return on Equity (-2.22%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cardiovascular Systems's financial position?


Financial Position Analysis

Short Term Liabilities: CSII's short term assets ($161.9M) exceeds its short term liabilities ($46.9M)

Long Term Liabilities: CSII's short term assets ($161.9M) exceeds its long term liabilities (28.1M)


Debt to Equity History and Analysis

Debt Level: CSII is debt free.

Reducing Debt: CSII has no debt compared to 5 years ago when its debt to equity ratio was 0.8%.


Balance Sheet

Inventory Level: CSII has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CSII's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CSII has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CSII is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 28.6% per year.


Next Steps

Dividend

What is Cardiovascular Systems's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CSII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CSII's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CSII's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CSII's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CSII's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cardiovascular Systems's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Scott Ward (59yo)

3.3yrs

Tenure

US$4,575,582

Compensation

Mr. Scott Raymond Ward, MS, B.Sc., has been the Chief Executive Officer and President of Cardiovascular Systems Inc. since August 16, 2016 and served as an Interim Chief Executive Officer and Interim Presi ...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD4.58M) is about average for companies of similar size in the US market ($USD3.87M).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.3yrs

Average Tenure

51yo

Average Age

Experienced Management: CSII's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

4.0yrs

Average Tenure

57.5yo

Average Age

Experienced Board: CSII's board of directors are considered experienced (4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Sandra Sedo (55yo)

    Chief Compliance Officer

    • Tenure: 2.3yrs
    • Compensation: US$840.72k
  • Scott Ward (59yo)

    Chairman

    • Tenure: 3.3yrs
    • Compensation: US$4.58m
  • Jack Nielsen

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Alexander Rosenstein (47yo)

    General Counsel & Corporate Secretary

    • Tenure: 4.7yrs
    • Compensation: US$995.92k
  • David Whitescarver (61yo)

    Vice President of Corporate Development & Intellectual Property

    • Tenure: 2.4yrs
  • Jeffrey Points (42yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
    • Compensation: US$1.07m
  • Rhonda Robb (51yo)

    Chief Operating Officer

    • Tenure: 1.8yrs
    • Compensation: US$1.99m
  • Ryan Egeland (44yo)

    Chief Medical Officer

    • Tenure: 0yrs
  • Stephen Rempe

    Vice President of Human Resources

    • Tenure: 0.5yrs

Board Members

  • Gus Lawlor (63yo)

    Independent Director

    • Tenure: 10.8yrs
    • Compensation: US$210.00k
  • Scott Ward (59yo)

    Chairman

    • Tenure: 3.3yrs
    • Compensation: US$4.58m
  • Billy Cohn (59yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$190.00k
  • Ned Brown (56yo)

    Lead Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$240.00k
  • Martha Aronson (52yo)

    Independent Director

    • Tenure: 2.8yrs
    • Compensation: US$200.00k
  • Erik Paulsen (54yo)

    Independent Director

    • Tenure: 0.3yrs
  • Stephen Stenbeck

    Independent Director

    • Tenure: 0yrs

Company Information

Cardiovascular Systems, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cardiovascular Systems, Inc.
  • Ticker: CSII
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.559b
  • Shares outstanding: 35.20m
  • Website: https://www.csi360.com

Number of Employees


Location

  • Cardiovascular Systems, Inc.
  • 1225 Old Highway 8 Northwest
  • St. Paul
  • Minnesota
  • 55112
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CSIINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2009

Biography

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers periphera ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/21 23:57
End of Day Share Price2019/11/21 00:00
Earnings2019/09/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.